Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews

Psychopharmacology

Volumn 231, Issue 22, 2014, Pages 4301-4307

  Khan, Arif ^a,b   Faucett, James ^a   Brown, Walter A ^c  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Antidepressant clinical trials; Levomilnacipran; MADRS; Psychiatric interview methods; Psychological evaluation; SIGMA; Vilazodone

Indexed keywords

ANTIDEPRESSANT AGENT; BENZOFURAN DERIVATIVE; CYCLOPROPANE DERIVATIVE; INDOLE DERIVATIVE; MILNACIPRAN; PIPERAZINE DERIVATIVE; VILAZODONE;

ADULT; FEMALE; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PLACEBO EFFECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

ADULT; ANTIDEPRESSIVE AGENTS; BENZOFURANS; CYCLOPROPANES; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84939891524     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3584-4     Document Type: Article

References (19)

1. Cogger KO (2007) Rating rater improvement: a method for estimating increased effect size and reduction of clinical trial costs. J Clin Psychopharmacol 27:418-419
2. Engelhardt N, Feiger AD, Cogger KO, Sikich D, DeBrotta DJ, Lipsitz JD et al (2006) Rating the raters: assessing the quality of Hamilton Depression Rating Scale for Depression Clinical Interviews in Two Industry-Sponsored Clinical Drug Trials. J Clin Psychopharmacol 26:71-74
3. Joyce PR, Paykel ES (1989) Predictors of drug response in depression. Arch Gen Psychiatry 46:89-99
4. Khan A, Leventhal RM, Khan SR, Brown WA (2002) Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database. J Clin Psychopharmacol 22:39-45
5. Khan A, Detke M, Khan SRF, Mallinckrodt C (2003) Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis 191:211-218
6. Khan A, Broadhead AE, Kolts RL, Brown WA (2005) Severity of depressive symptoms and response to antidepressants in antidepressant trials. J Psychiatr Res 39:145-150
7. Khan A, Faucett J, Brown W (2014) Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews. J Psychiatr Res 51:88-92
8. Kobak KA, Feiger AD, Lipsitz JD (2005) Interview quality and signal detection in clinical trials. Am J Psychiatry 162:628
9. Kobak KA, Kane JM, Thase ME, Nierenberg AA (2007) Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 27:1-5
10. Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JB, Cook IA et al (2010) Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol 30:193-197
11. Lipsitz J, Kobak K, Feiger A, Sikich D, Moroz G, Engelhardt N (2004) The rater applied performance scale: development and reliability. Psychiatry Res 127:147-155
12. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatr 134:382-389
13. Oren D, Marcus R, Pultz J, Dockens R, Croop R, Coric V, et al. (2008) A clinical trial of corticotropin releasing factor receptor-1 antagonist (CRF1) for the treatment of major depressive disorder. In: Annual Meeting of the American College of Neuropsychopharmacology; December 7-11, Scottsdale, AZ. Poster Presentation
14. Rush AJ (2000) The inventory of depressive symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR). Int J Methods Psychiatr Res 9(2):45-59
15. Papakostas G, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19:34-40
16. Rutherford BR, Sneed JR, Roose SP (2009) Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 78:172-181
17. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y et al (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 71(3):270-279
18. Targum SD, Wedel PC, Robinson J, Daniel DG, Busner J, Bleicher LS et al (2013) A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of major depressive disorder. Journal of Psychiatr Res 47:944-954
19. Williams JW, Kobak K (2008) Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA). Br J Psychiatry 192:52-58